Inactivating alterations to MHC class I molecules, through augmentation or deletion of components HLA-A/B/C or β2 microglobulin (B2M) is common among DLBCL in both GCB and ABC types, and results in failed expression of surface MHC class I and subsequent failure to activate cytotoxic CD8+ T cells (Challa-Malladi et al., 2011). The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.